Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

Bortezomib, a proteasome inhibitor with efficacy in multiple myeloma, is associated with thrombocytopenia, the cause and kinetics of which are different from those of standard cytotoxic agents. We assessed the frequency, kinetics, and mechanism of thrombocytopenia following treatment with bortezomib...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lonial, Sagar, Waller, Edmund K., Richardson, Paul G., Jagannath, Sundar, Orlowski, Robert Z., Giver, Cynthia R., Jaye, David L., Francis, Dixil, Giusti, Sara, Torre, Claire, Barlogie, Bart, Berenson, James R., Singhal, Seema, Schenkein, David P., Esseltine, Dixie-Lee W., Anderson, Jessica, Xiao, Hugh, Heffner, Leonard T., Anderson, Kenneth C.
Formato: Artigo
Idioma:Inglês
Publicado em: The American Society of Hematology 2005
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895114/
https://ncbi.nlm.nih.gov/pubmed/16099887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-03-1173
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados